Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Carol Yee Kwan Chan"'
Autor:
Sang Hoon Ahn, Alnoor Ramji, Scott Fung, Chi-Yi Chen, Hie-Won Hann, Yang Zhao, Shalini Sethi, Wan-Long Chuang, Ho Bae, Leland J. Yee, John F. Flaherty, Carol Yee Kwan Chan, Young-Suk Lim, Xiaoli Ma, Pietro Lampertico, Yoon Jun Kim, Jia-Horng Kao, Anuj Gaggar, Edward Tam, Henry Lik-Yuen Chan, June Sung Lee
Publikováno v:
Clinical Hepatology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::db08222339b73d852ae8bca8f37b8a69
https://doi.org/10.1136/gutjnl-2021-iddf.82
https://doi.org/10.1136/gutjnl-2021-iddf.82
Autor:
Sang Hoon Ahn, Giulio Marchesini, Carla S. Coffin, Wan-Long Chuang, Aric J. Hui, Yi-Hsang Huang, Yang Zhao, Susanna K. Tan, Tak Yin Owen Tsang, Magdy Elkhashab, Sayed-Mohammed Jafri, Chien-Hung Chen, Harry La Janssen, Jeong Heo, John F. Flaherty, Diana M. Brainard, Claire Fournier, Kosh Agarwal, Carol Yee Kwan Chan, Young-Suk Lim, Anuj Gaggar, Edward Gane, Vithika Suri, Pietro Lampertico
Publikováno v:
Clinical Hepatology.
Background We have previously shown in renally impaired (RI) CHB patients, including those with ESRD on HD, that switching to TAF from TDF and/or other OAVs maintains high rates of viral suppression with stable bone and renal safety parameters at Wee
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::15afebbf2a4d1d0f6690a80bc2b37cb6
https://doi.org/10.1136/gutjnl-2021-iddf.80
https://doi.org/10.1136/gutjnl-2021-iddf.80
Autor:
Harry La Janssen, Chun-Yen Lin, Aric J. Hui, Huy N. Trinh, Claire Fournier, Yang Zhao, Ho Bae, Vithika Suri, Stephen D. Ryder, John F. Flaherty, Young-Suk Lim, Anuj Gaggar, Carol Yee Kwan Chan, Susanna K. Tan, Dianna M Brainard, Jeong Heo, Wan-Long Chuang, Tak Yin Owen Tsang
Publikováno v:
Clinical Hepatology.
Background We have previously shown that in hepatically impaired CHB patients, switching to TAF from TDF and/or other OAVs maintains high rates of viral suppression with stable bone and renal safety parameters through 48 weeks. Here we present our fi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9923530515d1ce5de0293f9b7eda7795
https://doi.org/10.1136/gutjnl-2021-iddf.81
https://doi.org/10.1136/gutjnl-2021-iddf.81
Autor:
Grace Lai-Hung Wong, Mang Ma, Namiki Izumi, Maria Buti, Carol Yee Kwan Chan, Calvin Q. Pan, Edward Gane, Shalimar, Young-Suk Lim, Scott Fung
Publikováno v:
Clinical Hepatology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8bccbb2271cf4ac2691f56e2ac497dc8
https://doi.org/10.1136/gutjnl-2021-iddf.79
https://doi.org/10.1136/gutjnl-2021-iddf.79
Autor:
Shalini Sethi, Belinda Jump, John F. Flaherty, Carol Yee Kwan Chan, Jia-Horng Kao, Tuan Trong Nguyen, Sang Hoon Ahn, George Y. Wu, Leland J. Yee, Fung Scott, Anuj Gaggar, Seung Woon Paik, Hie-Won Hann, Huy N. Trinh
Publikováno v:
Abstracts.
Background In a recent Phase 3 study (Study 4018) in HBV patients suppressed on TDF treatment, switching to TAF demonstrated non-inferior efficacy to continued TDF with superior bone and renal safety at Week 48. This study is to assess the safety and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8ec72a15741200d76783f8cc4ffdeda5
https://doi.org/10.1136/gutjnl-2020-iddf.141
https://doi.org/10.1136/gutjnl-2020-iddf.141
Autor:
Heribert Ramroth, Mei Lu, Anand P. Chokkalingam, John F. Flaherty, Raymond Kim, Carol Yee Kwan Chan, Anuj Gaggar, Laura Telep, Stuart C. Gordon
Publikováno v:
Abstracts.
Background TDF and ETV are first-line treatments for CHB virus infection. A recent analysis of nationwide insurance data from Korea suggested that the risk of HCC may vary by type of CHB treatment; however, this finding was based on a limited follow-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::379e2a74575352deaf291824d019c8ca
https://doi.org/10.1136/gutjnl-2020-iddf.140
https://doi.org/10.1136/gutjnl-2020-iddf.140
Autor:
Anuj Gaggar, Kathryn Kersey, Kathleen B. Schwarz, Philip J. Rosenthal, Sean Hsueh, Jessica Wen, Karen F. Murray, Gabriella Verucchi, William F. Balistreri, Daniel Leung, Carol Yee Kwan Chan, Michael R. Narkewicz, Maureen M. Jonas, Etienne Sokal, Sanjay Bansal, Jiang Shao, Regino P. Gonzalez-Peralta, Chuan-Hao Lin, Rene Romero
Publikováno v:
Abstracts.
Background DAA regimens have been approved for CHC treatment in 12 to Methods Patients 6 to Results 102 patients 12 to 15%) were headache, fatigue, and nausea in adolescents and vomiting, cough and headache in 6 to Conclusions In patients 6 to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ec7f84a8d7dfd68c2cf897c781ef67ed
https://doi.org/10.1136/gutjnl-2020-iddf.142
https://doi.org/10.1136/gutjnl-2020-iddf.142